Sat, Sep 20, 2014, 2:51 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Genetic Technologies Limited Message Board

  • one_up_on_wall_street one_up_on_wall_street Nov 27, 2012 9:44 AM Flag

    AMBUSH AT ANNUAL SHAREHOLDERS MEETING!

    Ambush at AGM leaves Genetic Tech without chairman and CEO
    BY: CRITERION From: The Australian November 28, 2012 12:00AM

    Source: The Australian
    SMALL-CAP annual general meetings are usually breezy affairs with plenty of back-slapping, a few cursory questions followed by refreshments.

    In the case of Genetic Technologies (GTG, 8.7c), an ambush loomed and by the end of the day the genetic tester would be devoid of its chairman, chief executive and two other directors.

    While we gather he didn't speak at the meeting, Genetic founder Mervyn Jacobson used his 29 per cent stake to block the re-election of chairman Mel Bridges, who has had a 30-year healthcare career.

    A motion to re-elect fellow director Huw Jones also failed. Shortly after, chief executive Paul MacLeman and director Greg Brown (who was re-elected) resigned, as did legal and corporate development head David Sparling.

    After the meet, Bridges said it was "regrettable that a company with the potential of GTG was unable to reach middle ground with its major shareholder".

    Genetic's sometimes controversial business looked to be headed in the right direction, with strong take-up of its Brevagen product in the US. But yesterday's meet was one Jacobson production that should never have seen the limelight.

    We'll avoid this train smash.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Despite the rejoicing by shareholders, it is a surprise that the POS Greg Brown AKA master of the destruction of IPD (ASX listed ImpediMed) and Bridges desciple was re-elected (let's keep the blithering idiot for grins). Stop caring for the mentally impaired - this is business.

      Sentiment: Strong Sell

    • one_up_on_wall_street one_up_on_wall_street Nov 27, 2012 12:44 PM Flag

      My big question is what does Mervyn Jacobson have up his sleeves? I don't think he thought CEO Paul McCl would leave. What now is he going to do?

      • 2 Replies to one_up_on_wall_street
      • filipyew@y7mail.com filipyew Nov 27, 2012 3:31 PM Flag

        When the going gets tough the CEO resigns instead of fighting tooth and nail to support whatever he believes he should be doing ie looks after the company.The company might be better without him.I think the share price may improve with a better executive team with vision.The board must acknowledge that it is the shareholders who own the company and the board is the caretaker and its role is to look after the interests of the company but not themselves. Good on you all shareholders who voted for the interests of the company ie yourselves, the shareholders.I have lost too much money on this company because of the incompetence of the the management.

        Sentiment: Strong Buy

      • filipyew@y7mail.com filipyew Nov 27, 2012 3:03 PM Flag

        I think we need a new CEO who would be able to steer the company into prominence. With an excellent product like Brevagen and the the depressing share price is just a poor reflection the performance of the executive team.Brevagen should be advertised from the roof tops as it is a life saving test like Bracanalysis of Myriad Gennetics.I don't think the senior management has done enough to promote the excellent product the company has.Let's hope a more competent new management may be able to carry the product to where it should be ie more sales and benefits to potential breast cancer sufferers.

        Sentiment: Strong Buy

 
GENE
0.5579-0.0181(-3.14%)Sep 19 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.